Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neoplasms | D009369 | — | C80 | 1 | 1 | — | — | — | 1 |
Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | 1 | — | — | — | 1 |
Fallopian tube neoplasms | D005185 | — | — | — | 1 | — | — | — | 1 |
Non-small-cell lung carcinoma | D002289 | — | — | — | 1 | — | — | — | 1 |
Adenocarcinoma | D000230 | — | — | — | 1 | — | — | — | 1 |
Drug common name | Farletuzumab |
INN | farletuzumab |
Description | Farletuzumab (humanized mab) |
Classification | Antibody |
Drug class | monoclonal antibodies |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL1743016 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | — |
UNII ID | 2O09BG0OWA (ChemIDplus, GSRS) |